Application of PK-PD Modeling in Understanding Bystander Effect for Antibody Drug Conjugates

被引：0
|
作者：
Singh, Aman P. [1 ]
Shah, Dhaval K. [1 ]
机构：
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-041
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [31] Utility of PK-PD modeling to guide product enhancement strategy
    Gao, Xiang
    Benincosa, Lisa
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1063 - 1063
  • [32] EFFECT OF RENAL FUNCTION ON EDOXABAN PHARMACOKINETICS (PK) AND ON POPULATION PK/PK-PD MODEL
    Ridout, G.
    de la Motte, S.
    Niemezyk, S.
    Sramck, P.
    Johnson, L.
    Jin, J.
    He, L.
    Mendell, J.
    Salazar, D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1124 - 1124
  • [33] The cytotoxicity of antibody-drug conjugates to bystander cells
    Kovtun, Y.
    Erickson, H.
    Kellogg, B.
    Steeves, R.
    Widdison, W.
    Garrett, L.
    Chari, R.
    Lutz, R.
    Blattler, W.
    Goldmacher, V.
    EJC SUPPLEMENTS, 2006, 4 (12): : 67 - 67
  • [34] Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
    Zhang, Wantong
    Zhu, Baochen
    Cao, Weiyi
    Li, Rui
    Wang, Shuge
    Gao, Rui
    TRIALS, 2018, 19
  • [35] Drug-receptor occupancy study in predicting proper dose of psychotropic drugs with PK-PD modeling
    Kim, E.
    Howes, O.
    Kapur, S.
    Kwon, J. S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 14 - 15
  • [36] Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling of xenograft tumor response of Trastuzumab-DM1-antibody drug conjugates
    Wada, R.
    Erickson, H. K.
    Phillips, G. Lewis
    Provenzano, C. A.
    Leipold, D. D.
    Pinkas, J.
    Mai, E.
    Gupta, M.
    Johnson, H.
    Tibbitts, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 77 - 77
  • [37] PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration
    Robertson, SA
    Lascelles, BDX
    Taylor, PM
    Sear, JW
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2005, 28 (05) : 453 - 460
  • [38] PK-PD modeling of cetrorelix effects on circadian testosterone production.
    Derendorf, H
    Hermann, R
    Romeis, P
    Locher, M
    Schnaars, Y
    Riethmüller-Winzen, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 156 - 156
  • [39] Understanding the dose-response relationship of a pro-apoptotic compound in mice through PK-PD modeling
    Pierrillas, P.
    Henin, E.
    Bouzom, F.
    Tod, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 19 - 19
  • [40] CONCEPTUAL FRAMEWORK AND CASE STUDIES FOR IMPLEMENTATION OF PK-PD IN ADME/DRUG DISCOVERY
    Chimalakonda, Anjaneya P.
    DRUG METABOLISM REVIEWS, 2012, 44 : 6 - 6
12345